Intervacc AB Share Price Nasdaq Stockholm
Equities
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- SEK | - |
05-15 | Intervacc AB Announces Board Appointments | CI |
05-15 | Intervacc AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Sales 2024 * | 19.2M 1.79M 141M | Sales 2025 * | 53.1M 4.96M 390M | Capitalization | 329M 30.75M 2.42B |
---|---|---|---|---|---|
Net income 2024 * | -77M -7.19M -566M | Net income 2025 * | -66M -6.16M -485M | EV / Sales 2024 * | 11.1 x |
Net cash position 2024 * | 116M 10.83M 852M | Net cash position 2025 * | 55M 5.13M 404M | EV / Sales 2025 * | 5.17 x |
P/E ratio 2024 * |
-4.26
x | P/E ratio 2025 * |
-5
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 78.16% |
Managers | Title | Age | Since |
---|---|---|---|
Jonas Sohlman
CEO | Chief Executive Officer | - | 20/08/23 |
Jan Persson
DFI | Director of Finance/CFO | - | 05/02/20 |
Andrew Waller
CTO | Chief Tech/Sci/R&D Officer | - | 10/06/20 |
Members of the board | Title | Age | Since |
---|---|---|---|
Boel Sundvall
BRD | Director/Board Member | 65 | 31/12/22 |
Chairman | 56 | - | |
Edwin Torr
BRD | Director/Board Member | 63 | - |
1st Jan change | Capi. | |
---|---|---|
+9.42% | 115B | |
+11.84% | 106B | |
-14.15% | 21.84B | |
-1.05% | 21.96B | |
-5.29% | 19.21B | |
-38.29% | 17.71B | |
-4.16% | 18.08B | |
+7.99% | 14.32B | |
+36.24% | 12.42B |